Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Nov-Dec;35(6):3001-3009.
doi: 10.21873/invivo.12595.

Screening Tools for Sarcopenia

Hiroki Nishikawa  1   2 , Akira Asai  3 , Shinya Fukunishi  3   2 , Toshihisa Takeuchi  3 , Masahiro Goto  3 , Takeshi Ogura  3 , Shiro Nakamura  3 , Kazuki Kakimoto  3 , Takako Miyazaki  3   2 , Shuhei Nishiguchi  4 , Kazuhide Higuchi  3
Affiliations
Review

Screening Tools for Sarcopenia

Hiroki Nishikawa et al. In Vivo. 2021 Nov-Dec.

Abstract

The elderly people are characterized by multiple comorbidities, dementia, and are at risk of developing sarcopenia and frailty. Sarcopenia is defined by loss of muscle mass and muscle strength or physical decline. Sarcopenia is a main component of physical frailty. Screening tools for sarcopenia that can be easily determined in daily practice are useful and include the SARC-F screening tool. SARC-F is a questionnaire consisting of five questions: Strength (S), Assistance walking (A), Rising from a chair (R), Climbing stairs (C), and Falls (F) on a scale of 0 to 2. The recommended cutoff value is ≥4 points. The SARC-F has been shown to correlate well with clinical outcomes in the elderly and various underlying diseases, while it is also true that the SARC-F has its shortcomings such as low sensitivity for sarcopenia. In this review, we mainly outline the SARC-F and mention other screening tools for sarcopenia.

Keywords: SARC-F; Sarcopenia; review; screening tool; sensitivity; specificity.

PubMed Disclaimer

Conflict of interest statement

The Authors have no conflicts of interest to declare in relation to this study.

References

    1. Nakagawa T, Cho J, Yeung DY. Successful aging in East Asia: Comparison among China, Korea, and Japan. J Gerontol B Psychol Sci Soc Sci. 2021;76(Suppl 1):S17–S26. doi: 10.1093/geronb/gbaa042. - DOI - PMC - PubMed
    1. Cabinet Office website. Available at: http://www8.cao.go.jp/kourei/whitepaper/index-w. html. Last accessed on September 30, 2021.
    1. Chen LK, Woo J, Assantachai P, Auyeung TW, Chou MY, Iijima K, Jang HC, Kang L, Kim M, Kim S, Kojima T, Kuzuya M, Lee JSW, Lee SY, Lee WJ, Lee Y, Liang CK, Lim JY, Lim WS, Peng LN, Sugimoto K, Tanaka T, Won CW, Yamada M, Zhang T, Akishita M, Arai H. Asian Working Group for Sarcopenia: 2019 consensus update on sarcopenia diagnosis and treatment. J Am Med Dir Assoc. 2020;21(3):300–307.e2. doi: 10.1016/j.jamda.2019.12.012. - DOI - PubMed
    1. Nishikawa H, Fukunishi S, Asai A, Nishiguchi S, Higuchi K. Sarcopenia and frailty in liver cirrhosis. Life (Basel) 2021;11(5):399. doi: 10.3390/life11050399. - DOI - PMC - PubMed
    1. World Health Organization. Ageing and life course. 2009 [cited 2009 April 30] Available at: http//www.who.int/ageing/en. Last accessed on September 30, 2021.

LinkOut - more resources